Social network
Our responsibility

Tools content (print, share, increase/decrease text size):



Developing the first candidate dengue vaccine

After working to develop a dengue vaccine for over 20 years, we are now within reach of our goal of making dengue the next vaccine-preventable disease. The Sanofi Pasteur candidate vaccine is the most clinically and industrially advanced dengue vaccine candidate in development and the first candidate dengue vaccine to successfully complete a Phase III clinical efficacy study.

Dengue vaccine prequalification period Sanofi Pasteur site in Neuville-sur-Saône - France

Dengue vaccine prequalification period,
site Neuville-sur-Saône - France


We have invested 1.5 billion euros in dengue vaccine R&D and production including €350 million in state-of-the-art vaccine production facilities and we are partnering with global stakeholders and local governments to improve dengue surveillance, detection, diagnostics and infrastructure in endemic areas.

First vaccine against dengue site in Val de Reuil - France

First vaccine against dengue, site Val de Reuil - France


© Sanofi 2004-2017 - All rights reserved - Update: November 28, 2016

  • Site complies with W3C WCAG 2.0 (new window, in english)